Jazz Pharmaceuticals (JAZZ) Expected to Announce Quarterly Earnings on Wednesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) is expected to issue its quarterly earnings data after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of $5.83 per share and revenue of $1.06 billion for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Jazz Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ JAZZ opened at $135.39 on Wednesday. The firm has a market cap of $8.19 billion, a price-to-earnings ratio of 19.07, a PEG ratio of 0.92 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $138.27. The business’s 50 day moving average is $123.73 and its two-hundred day moving average is $117.41.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the transaction, the chief executive officer now owns 427,025 shares in the company, valued at approximately $51,742,619.25. The trade was a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders sold 5,053 shares of company stock worth $617,442. Corporate insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

JAZZ has been the topic of a number of research analyst reports. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. TD Cowen cut their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Robert W. Baird upped their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $180.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.